Stock listing
Frankfurt:F3Y Microba Life Sciences Limited Aktie
German listing (Frankfurt) of Microba Life Sciences Limited · home listing ASX:MAP
Follow Microba Life Sciences Limited into a list and get an email when it puts out news.
Share price · FWB:F3Y
€0.018 EUR +0.001 (+6.1%)
Close on Nov 12, 2026
- Day range
- €0.018 – €0.018 EURNov 12, 2026
- Market cap
- €12.55M EURAt the close on Nov 12, 2026 · price × 717.1M shares outstanding
- Traded on an average day
- €5 EURMedian day 0 shares · 61 days with no trades · last 3 months, Aug 12, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:MAP · Home | $0.036 AUD | 0.000 (0.0%) | — | $0.036 | $0.036 | $0.036 | $0.036 | Close on Nov 19, 2026 |
| Frankfurt:F3Y | €0.018 EUR | +0.001 (+6.1%) | — | €0.018 | €0.018 | €0.018 | €0.017 | Close on Nov 12, 2026 |
Daily closes
Last 3 months, Aug 12, 2026 – Nov 6, 2026 · FWB:F3Y · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.018 | 0.000 | 0.0% | €0.018 | €0.018 | €0.018 | 0 | |
| €0.018 | 0.000 | 0.0% | €0.018 | €0.018 | €0.018 | 0 | |
| €0.018 | 0.000 | 0.0% | €0.018 | €0.018 | €0.018 | 0 | |
| €0.018 | +0.001 | +5.9% | €0.018 | €0.018 | €0.018 | 0 | |
| €0.017 | +0.001 | +6.3% | €0.017 | €0.017 | €0.017 | 0 | |
| €0.016 | -0.002 | -11.1% | €0.017 | €0.018 | €0.016 | 0 | |
| €0.018 | 0.000 | 0.0% | €0.018 | €0.018 | €0.018 | 0 | |
| €0.018 | 0.000 | 0.0% | €0.018 | €0.018 | €0.018 | 0 | |
| €0.018 | 0.000 | 0.0% | €0.018 | €0.018 | €0.018 | 0 | |
| €0.018 | 0.000 | 0.0% | €0.018 | €0.019 | €0.018 | 0 | |
| €0.018 | -0.001 | -5.3% | €0.018 | €0.018 | €0.018 | 0 | |
| €0.019 | -0.001 | -5.0% | €0.019 | €0.019 | €0.019 | 0 | |
| €0.020 | -0.003 | -13.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.023 | 0.000 | 0.0% | €0.023 | €0.023 | €0.023 | 0 | |
| €0.023 | +0.002 | +9.5% | €0.023 | €0.023 | €0.023 | 0 | |
| €0.021 | +0.001 | +5.0% | €0.021 | €0.021 | €0.021 | 0 | |
| €0.020 | -0.005 | -20.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.025 | -0.001 | -3.8% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.026 | +0.003 | +13.0% | €0.026 | €0.026 | €0.026 | 0 | |
| €0.023 | -0.004 | -14.8% | €0.023 | €0.023 | €0.023 | 0 | |
| €0.027 | +0.001 | +3.8% | €0.026 | €0.027 | €0.026 | 0 | |
| €0.026 | 0.000 | 0.0% | €0.026 | €0.026 | €0.026 | 0 | |
| €0.026 | +0.001 | +4.0% | €0.026 | €0.026 | €0.026 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.026 | €0.025 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.025 | -0.002 | -7.4% | €0.025 | €0.026 | €0.025 | 0 | |
| €0.027 | +0.001 | +3.8% | €0.026 | €0.037 | €0.026 | 4,800 | |
| €0.026 | 0.000 | 0.0% | €0.026 | €0.026 | €0.026 | 0 | |
| €0.026 | -0.001 | -3.7% | €0.026 | €0.026 | €0.026 | 0 | |
| €0.027 | -0.009 | -25.0% | €0.027 | €0.027 | €0.027 | 0 | |
| €0.036 | +0.011 | +44.0% | €0.026 | €0.036 | €0.026 | 4,800 | |
| €0.025 | -0.003 | -10.7% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.028 | 0.000 | 0.0% | €0.028 | €0.028 | €0.028 | 0 | |
| €0.028 | 0.000 | 0.0% | €0.028 | €0.028 | €0.028 | 0 | |
| €0.028 | -0.001 | -3.4% | €0.028 | €0.028 | €0.028 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | -0.001 | -3.3% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.030 | 0.000 | 0.0% | €0.030 | €0.030 | €0.030 | 0 | |
| €0.030 | 0.000 | 0.0% | €0.030 | €0.030 | €0.030 | 0 | |
| €0.030 | +0.001 | +3.4% | €0.030 | €0.030 | €0.030 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | +0.001 | +3.6% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.028 | -0.001 | -3.4% | €0.028 | €0.028 | €0.028 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | 0.000 | 0.0% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.029 | -0.001 | -3.3% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.030 | +0.001 | +3.4% | €0.030 | €0.030 | €0.030 | 0 | |
| €0.029 | -0.001 | -3.3% | €0.029 | €0.029 | €0.029 | 0 | |
| €0.030 | -0.001 | -3.2% | €0.030 | €0.030 | €0.030 | 0 | |
| €0.031 | +0.003 | +10.7% | €0.031 | €0.031 | €0.031 | 0 | |
| €0.028 | +0.003 | +12.0% | €0.028 | €0.028 | €0.028 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.025 | €0.025 | 0 | |
| €0.025 | 0.000 | 0.0% | €0.025 | €0.025 | €0.025 | 0 |
- Ticker
- Frankfurt:F3Y
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
BCAL Position on GSS-MAP Merger
Latest deck · Jul 16, 2026
Investor Presentation (July 2026)
Investor deck · 25 slides
Latest news
Cleansing Notice
Oct 28, 2026
Closed €0.018 (0.0%) on Oct 28, 2026
Application for quotation of securities - MAP
Oct 27, 2026
Closed €0.018 (0.0%) on Oct 28, 2026
Microba Life Sciences Limited on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 48 in the last 12 months · 122 in all · newest Nov 19, 2026 · oldest 2022
- Calls
- 10 calls with a replay · 10 with a transcript · latest Jul 22, 2025
- Decks
- 43 decks · latest Jul 16, 2026
Where Microba Life Sciences Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:MAP · Home listing | ASX | Australia | AUD |
| Frankfurt:F3Y · This page | Frankfurt | Germany | EUR |
Cash and shares
Jun 2026 deck · Microba Life Sciences — Investor Presentation (June 2026)
- Cash
- $7.28 million
Valuation
EV/sales 1.6× against a median of 2.9×: 3rd lowest of 9 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 19, 2026
- Enterprise value
- $22.90M AUD
- P/E
- Loss
- EV/sales
- 1.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.1×
- Gross margin
- −79.5%
- Operating margin
- −137.6%
- Net margin
- −140.4%
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Microba Life Sciences Limited · ASX:MAP | US$17.70M | US$15.16M | n/a | 1.6× | n/a | 1.1× | −140.4% | 0.2× | n/a |
| TFBS Bioscience, Inc. · TPEX:6939 | US$19.81M | US$7.83M | n/a | 1.3× | n/a | 0.6× | −38.6% | 0.0× | n/a |
| SANIGEN Co., Ltd. · KRX:188260 | US$19.66M | US$10.06M | n/a | 2.2× | n/a | 2.3× | −82.6% | 0.1× | n/a |
| NanoRepro AG · XETR:NN6 | US$19.45M | US$11.45M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | n/a |
| Urteste S.A. · GPW:URT | US$19.24M | US$19.10M | n/a | 3,525× | n/a | 3.5× | n/a | 0.0× | n/a |
| Genematrix Inc. · KRX:109820 | US$19.06M | US$6.80M | n/a | 0.8× | 31.7× | 1.4× | −1.7% | 0.0× | n/a |
| Oxford BioDynamics PLC · LSE:OBD | US$18.46M | US$20.77M | n/a | 14.5× | n/a | 4.3× | n/a | 1.3× | n/a |
| RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. · BIST:RTALB | US$18.41M | US$16.94M | 1.1× | 3.6× | 61.6× | 0.3× | 367.8% | 0.0× | n/a |
| Nexsen Limited · ASX:NXN | US$18.05M | US$15.08M | n/a | n/a | n/a | 4.8× | n/a | 0.0× | n/a |
| Genedrive PLC · LSE:GDR | US$17.85M | US$18.00M | n/a | 18.0× | n/a | n/a | −684.7% | n/a | n/a |
| PlexBio Co., Ltd. · TPEX:6572 | US$15.79M | US$7.19M | n/a | 1.9× | n/a | 1.8× | −49.1% | 0.0× | n/a |
| Median of the others | US$18.76M | US$13.26M | 1.1× | 2.9× | 46.7× | 1.8× | −43.9% | 0.0× |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.082 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.018 · 1 analyst
- Revenue, year to Jun 2027
- 15.36M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Luke Reid | Chief Executive Officer |
| James Heath | Chief Financial Officer and Company Secretary |
| Alaster Stockwell-Jones | Managing Director (UK) |
| Associate Professor Lutz Krause | Chief Scientific Officer |
| David Wood | Chief Technology Officer |
| Keith Byrne | Head of Test Operations |
Board
| Director | Role |
|---|---|
| Ian Frazer AC | Deputy Chairman of the Board, Chair of Medical Advisory Board |
| Pasquale Rombola | Chairman of the Board |
Events
Calls
| Call | When | Status |
|---|---|---|
| Microba Life Sciences (ASX:MAP) Q4 2025 Earnings Call | Tue, Jul 22, 2025 | Replay |
| Microba Life Sciences (ASX:MAP) Q3 2025 Earnings Call | Tue, Apr 29, 2025 | Replay |
| Microba Life Sciences (ASX:MAP) Q2 2025 Earnings Call | Tue, Jan 28, 2025 | Replay |
| Microba Life Sciences (ASX:MAP) Q1 2025 Earnings Call | Mon, Oct 28, 2024 | Replay |
| Microba Life Sciences (ASX:MAP) Q4 2024 Earnings Call | Wed, Jul 24, 2024 | Replay |
| Microba Life Sciences (ASX:MAP) Q3 2024 Earnings Call | Mon, Apr 22, 2024 | Replay |
| Microba Life Sciences (ASX:MAP) Q2 2024 Earnings Call | Fri, Jan 26, 2024 | Replay |
| Microba Life Sciences (ASX:MAP) Q4 2023 Earnings Call | Wed, Jul 26, 2023 | Replay |
| Microba Life Sciences (ASX:MAP) Q3 2023 Earnings Call | Wed, Apr 19, 2023 | Replay |
| Microba Life Sciences (ASX:MAP) Q2 2023 Earnings Call | Sat, Jan 28, 2023 | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Apr 23, 2026 | +1.4% |
| Q4 2025 | Mar 4, 2026 | +2.5% |
| Quarter to Sep 30, 2025 | Oct 27, 2025 | −4.9% |
| Q2 2025 | Aug 26, 2025 | −2.1% |
| Q1 2025 | Apr 17, 2025 | +2.8% |
| Q4 2024 | Feb 25, 2025 | +6.5% |
| Q3 2024 | Oct 28, 2024 | 0.0% |
| Q2 2024 | Aug 28, 2024 | −10.5% |
| Q1 2024 | Apr 22, 2024 | −8.1% |
| Q4 2023 | Feb 27, 2024 | +2.8% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 5, 2023 | −2.2% |
| Q2 2023 | Aug 29, 2023 | +2.9% |
| Q1 2023 | Apr 19, 2023 | +4.7% |
| Q4 2022 | Feb 22, 2023 | +1.3% |
| Q3 2022 | Nov 30, 2022 | −1.5% |
| Q2 2022 | Aug 25, 2022 | +5.0% |
| Q1 2022 | Apr 1, 2022 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 25 slides | Jul 16, 2026 |
| Investor Presentation (June 2026) | Investor deck | 33 slides | Jun 12, 2026 |
| Investor Presentation (April 2026) | Investor deck | 25 slides | Apr 30, 2026 |
| Investor Presentation (January 2026) | Investor deck | 60 slides | Jan 29, 2026 |
| Investor Presentation (October 2025) | Investor deck | 54 slides | Oct 28, 2025 |
| Investor Presentation (July 2025) | Investor deck | 57 slides | Jul 22, 2025 |
| Q4 2025 Earnings Presentation | Earnings | 56 slides | Jul 22, 2025 |
| Investor Presentation (June 2025) | Investor deck | 57 slides | Jun 23, 2025 |
| Investor Presentation (April 2025) | Investor deck | 49 slides | Apr 30, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 48 slides | Apr 29, 2025 |
All 43 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of fully paid ordinary shares Tranche closed: A$2.02M raised · A$0.04 a share | Oct 28, 2026 | US$1.41M |
| Private placement of fully paid ordinary shares with free attaching unlisted options Announced: about A$4M · A$0.05 a share · Warrants at A$0.0625 for 36 months · Morgans Corporate Limited +1 Dealers: Morgans Corporate Limited (co-lead), Canaccord Genuity (Australia) Limited (co-lead) Insiders: Any shares taken up by Directors under the Placement are subject to approval at the EGM Use of proceeds: Fund the group to cashflow break-even: core diagnostics growth in Australia and UK, new testing product, working capital and offer costs | Jun 12, 2026 | US$2.82M |
| Share purchase plan of fully paid ordinary shares with free attaching unlisted options Announced: up to A$1M · A$0.05 a share · Warrants at A$0.0625 for 36 months Use of proceeds: Working capital | Jun 12, 2026 | US$704,586 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.8M | 15.7M | 12.1M | 5.42M | 4.69M | 3.73M | 2.91M | 1.83M |
| Cost of revenue | 26.5M | 8.23M | 6.18M | 12.2M | 2.32M | 9.04M | 6.96M | 4.32M |
| Gross profit | -11.7M | 7.44M | 5.91M | -6.77M | 2.37M | -5.30M | -4.05M | -2.49M |
| Research and development | 417.1K | 2.01M | 10.8M | 9.34M | 5.38M | 1.54M | 163.3K | |
| Selling, general and administrative | 15.5M | 17.0M | 12.2M | 7.81M | 8.57M | 822.0K | 1.98M | 1.10M |
| Operating income | -20.3M | -24.6M | -26.8M | -20.2M | -16.3M | -9.57M | -7.41M | -4.79M |
| Depreciation and amortization | 4.41M | 4.43M | 2.87M | 1.64M | 1.15M | 1.22M | 1.09M | 765.2K |
| EBITDA | -15.9M | -20.2M | -24.0M | -18.6M | -15.1M | -8.35M | -6.32M | -4.02M |
| Interest expense | 238.6K | 176.7K | 69.2K | 60.4K | 55.3K | 23.5K | 37.0K | 24.0K |
| Income before tax | -22.1M | -15.0M | -20.0M | -18.8M | -11.5M | -7.52M | -6.66M | -4.72M |
| Income tax | -1.37M | -106.6K | -51.3K | -6.09M | 9.23K | 1 | -6.52K | 13.0K |
| Net income | -20.7M | -14.9M | -19.9M | -12.7M | -11.5M | -7.52M | -6.65M | -4.73M |
| Earnings per share, basic | -0.03 | -0.03 | -0.05 | -0.04 | -0.04 | -0.03 | -0.02 | -0.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.95M | 11.7M | 20.9M | 32.0M | 30.6M | 13.0M | 6.90M | 11.0M |
| Short-term investments | 138.6K | 204.4K | 204.4K | 204.4K | 50.3K | |||
| Receivables | 3.21M | 4.11M | 8.10M | 7.24M | 3.42M | 1.65M | 622.8K | 162.3K |
| Inventory | 2.22M | 1.94M | 2.24M | 644.4K | 360.0K | 513.3K | 340.8K | 169.6K |
| Current assets | 13.9M | 19.0M | 32.2M | 41.5M | 35.8M | 16.2M | 8.11M | 11.5M |
| Property, plant and equipment | 3.87M | 3.91M | 2.58M | 2.81M | 1.20M | 1.63M | 1.60M | |
| Goodwill | 9.20M | 10.0M | 8.45M | |||||
| Total assets | 39.8M | 47.4M | 58.0M | 47.0M | 39.5M | 18.5M | 10.8M | 14.0M |
| Accounts payable | 2.64M | 2.35M | 3.70M | 2.98M | 813.2K | 353.5K | 392.3K | 267.0K |
| Current liabilities | 11.2M | 10.2M | 12.4M | 7.82M | 5.26M | 3.35M | 2.84M | 1.15M |
| Long-term debt | 364.5K | 468.7K | 0 | 0 | 135.9K | 277.2K | ||
| Total debt | 4.11M | 3.23M | 1.58M | 1.14M | 1.33M | 269.0K | 563.6K | 406.4K |
| Total liabilities | 15.4M | 14.9M | 16.8M | 8.23M | 5.94M | 3.55M | 3.10M | 1.43M |
| Shareholders' equity | 24.4M | 32.5M | 41.2M | 38.6M | 33.5M | 14.9M | 7.70M | 12.6M |
| Shares outstanding | 600.6M | 448.4M | 409.9M | 333.0M | 290.7M | 290.7M | 290.7M | 290.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.4M | -12.0M | -15.6M | -12.4M | -10.4M | -7.18M | -4.32M | -3.62M |
| Capital spending | -240.3K | -2.90M | -4.38M | -3.04M | -1.87M | -672.5K | -856.2K | -836.1K |
| Free cash flow | -12.6M | -14.9M | -19.9M | -15.4M | -1.87M | -7.85M | -5.18M | -4.46M |
| Cash from investing | -3.80M | -2.83M | -13.9M | -3.00M | -1.73M | -522.5K | -856.2K | -833.7K |
| Cash from financing | 12.8M | 5.58M | 18.4M | 16.7M | 29.2M | 13.8M | 1.08M | 13.7M |
| Dividends paid | -595.6K | -425.3K | ||||||
| Share buybacks | -714.6K | -384.7K | -1.26M | -595.6K | -1.90M | 15.1M | 1.40M | 10.6M |
| Change in cash | -3.79M | -9.15M | -11.2M | 1.46M | 17.6M | 6.13M | -4.10M | 11.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| BCAL Position on GSS-MAP Merger | Nov 18, 2026 | Acquisition or disposal | ASX |
| MAP: Proposed Merger with GSS not proceeding | Nov 17, 2026 | Acquisition or disposal | ASX |
| GSS: End of Proposed Merger with Microba Life Sciences | Nov 17, 2026 | Acquisition or disposal | ASX |
| Suspension from Quotation | Nov 16, 2026 | Trading halt or suspension | ASX |
| TOV: GSS - Panel Receives Application | Nov 13, 2026 | Other filings | ASX |
| Trading Halt Request | Nov 13, 2026 | Trading halt or suspension | ASX |
| Trading Halt | Nov 13, 2026 | Trading halt or suspension | ASX |
| Pause in Trading | Nov 12, 2026 | Trading halt or suspension | ASX |
| Cleansing Notice | Oct 28, 2026 | Financing | ASX |
| Application for quotation of securities - MAP | Oct 27, 2026 | Financing | ASX |
All 120 filings
Cap table
Built by 6ix from Microba Life Sciences Limited’s releases · as of Oct 28, 2026
- Common shares
- 742,742,274
- Fully diluted
- 742,742,274
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 742,742,274 | Oct 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 28, 2026 | 742,742,274 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alaster Stockwell-Jones | Managing Director (UK) · Since at least Nov 5, 2026 |
| Associate Professor Lutz Krause | Chief Scientific Officer · Since at least Nov 5, 2026 |
| David Wood | Chief Technology Officer · Since at least Nov 5, 2026 |
| Ian Frazer AC | Deputy Chairman of the Board, Chair of Medical Advisory Board · Since at least Nov 5, 2026 |
| James Heath | Chief Financial Officer and Company Secretary · Since at least Nov 5, 2026 |
| Keith Byrne | Head of Test Operations · Since at least Nov 5, 2026 |
| Luke Reid | Chief Executive Officer · Since at least Nov 5, 2026 |
| Pasquale Rombola | Chairman of the Board · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Microba Life Sciences Limited.